Overview

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

Status:
Completed
Trial end date:
2009-02-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Muscarinic Antagonists